Respiratory biologics market seen topping $33B by 2030

The respiratory biologics market is projected to grow sharply through 2030 as severe asthma, COPD and other hard-to-treat respiratory diseases drive demand for targeted therapies. North America is expected to lead the market, while Sanofi remains the top seller in the category.

Why it matters: - The respiratory biologics market is moving deeper into precision medicine as demand rises for therapies that can better control severe respiratory disease. - The market is projected to exceed $33 billion by 2030, making it a meaningful slice of the broader respiratory drugs and pharmaceuticals markets. - Growth in biologics could expand treatment options for patients whose symptoms are not adequately controlled by conventional therapies.

What happened: - The Business Research Company released its The Respiratory Biologics Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 27, 2026. - The report projects the respiratory biologics market will grow at a 15.9% compound annual growth rate through 2030. - The market is forecast to reach more than $33 billion by 2030. - The report estimates the broader respiratory diseases drugs market will reach about $220 billion by 2030. - Respiratory biologics are expected to account for about 15% of that parent market. - The segment is projected to represent nearly 1% of the overall pharmaceuticals industry, which the report pegs at $2,496 billion in 2030.

The details: - North America is expected to be the largest regional market, reaching $12.8 billion by 2030. - North America’s market is projected to rise from $6.2 billion in 2025 at a 15% CAGR. - The U.S. is forecast to be the top country in the market, reaching $11.4 billion by 2030. - The U.S. market is projected to grow from $5.7 billion in 2025 at a 15% CAGR. - Asthma is projected to be the largest disease segment, with about 67% of the market, or $22 billion, in 2030. - The report also covers chronic rhinosinusitis and hypereosinophilic syndrome as key disease segments. - The market is segmented by route of administration into intravenous and subcutaneous treatments. - Distribution runs through hospitals, specialty clinics, retail pharmacies and mail order pharmacies. - The asthma, chronic rhinosinusitis and hypereosinophilic syndrome segments are expected to generate more than $17 billion combined by 2030. - From 2025 to 2030, asthma is projected to add $11 billion, chronic rhinosinusitis $4 billion and hypereosinophilic syndrome $2 billion. - Sanofi S.A. held the largest global respiratory biologics sales position in 2025 with a 26% market share. - Sanofi’s specialty care portfolio includes biologic therapies for type 2 inflammatory diseases and severe respiratory conditions. - The report lists Sanofi, Regeneron Pharmaceuticals, F. Hoffmann-La Roche, AstraZeneca, GlaxoSmithKline, Amgen, Teva Pharmaceutical Industries, Boehringer Ingelheim, Merck & Co., Novartis, Pfizer, Vertex Pharmaceuticals, Kiniksa Pharmaceuticals, Glenmark Pharmaceuticals, Biogen and Pieris Pharmaceuticals among the active companies. - The top 10 companies accounted for 99% of total revenue in 2025. - The report names Thermo Fisher Scientific, Danaher’s Cytiva, Merck KGaA, Sartorius, Lonza, Fujifilm, AGC Biologics, Wacker Chemie, Repligen, Avantor, Bio-Rad, Corning, WuXi Biologics, Samsung Biologics, Catalent, Evonik, Asahi Kasei, Eppendorf and Charles River Laboratories as raw material suppliers. - The report lists Cencora, McKesson, Cardinal Health, Morris & Dickson, Anda, FFF Enterprises, Smith Drug, Dakota Drug, H. D. Smith, Owens & Minor, Kinray, Rochester Drug Cooperative, Value Drug Company, Imperial Distributors, Pharmaceutical Associates, D2 Solutions, CuraScript SD, Besse Medical and HDA Distribution Services as wholesalers and distributors. - End users include major health systems and hospitals such as Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Mount Sinai Health System, Kaiser Permanente, Apollo Hospitals, Fortis Healthcare, Max Healthcare Institute, Medanta The Medicity, National Jewish Health, Cedars-Sinai Medical Center, NewYork-Presbyterian Hospital, Stanford Health Care, Charité – Universitätsmedizin Berlin, Singapore General Hospital, King Faisal Specialist Hospital & Research Centre and Ramsay Health Care.

Between the lines: - The report points to a market shaped by severe disease burden, biomarker-driven treatment selection and wider use of targeted immune therapies. - A major share of revenue is concentrated among a small group of large drugmakers, reflecting high development costs, complex manufacturing and strict regulatory hurdles. - Sanofi’s lead position underscores how new approvals and expanded indications can quickly strengthen a company’s respiratory portfolio. - The FDA’s September 2024 approval of Dupixent as an add-on maintenance therapy for adults with inadequately controlled COPD and an eosinophilic phenotype is one example of how biologics are broadening beyond asthma. - The report frames the next growth wave around next-generation monoclonal antibodies, cytokine-targeted therapies, biomarker-guided treatments and subcutaneous formulations.

What's next: - Companies are expected to keep investing in biomarker-guided precision medicine and next-generation biologics for chronic airway disorders. - Strategic collaborations, licensing deals and geographic expansion are likely to remain central to competition. - The report expects supportive regulation, higher diagnosis rates and broader access to specialty care to keep driving market expansion through 2030. - More information - The full report

The bottom line: - Respiratory biologics are moving from niche use toward a larger role in respiratory care, with asthma, severe disease and precision medicine driving the market’s next phase of growth.